The Efficacy and Safety of Direct Oral Anticoagulants Compared to Warfarin for Left Ventricular Thrombus Resolution
Authors:
- Mariana Sousa PaivaMPMariana Sousa Paiva
- Francisco GamaFGFrancisco Gama
- Samuel AzevedoSASamuel Azevedo
- Pedro M. LopesPLPedro M. Lopes
- Francisco AlbuquerqueFAFrancisco Albuquerque
- Carla ReisCRCarla Reis
- Pedro FreitasPFPedro Freitas
- Sara GuerreiroSGSara Guerreiro
- João AbecasisJAJoão Abecasis
- Marisa TrabuloMTMarisa Trabulo
- António M. FerreiraAFAntónio M. Ferreira
- Regina RibeirasRRRegina Ribeiras
Open Access
- 20 March 2025
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (6) , 2129
Abstract
Background and Aim: Left ventricular thrombus (LVT) is a common complication of myocardial infarction (MI) and heart failure with reduced ejection fraction (HFrEF), typically managed with vitamin K antagonists (VKAs) for up to six months. However, data on direct oral anticoagulants (DOACs) for LVT treatment remain limited and conflicting. This study evaluates the effectiveness and safety of DOACs compared to warfarin for LVT resolution. Methods: We conducted a single-center retrospective cohort study of consecutive patients diagnosed with LVT from January 2010 to May 2024. The primary outcome was LVT resolution at 24 months. Safety outcomes included major bleeding and thromboembolic events. Diagnosis and follow-up were performed via echocardiography, with cardiac magnetic resonance and computed tomography as needed. Anticoagulant type, dose, duration, and concurrent antiplatelet therapy were at the treating physician’s discretion. Results: Among 171 patients (82.5% male, mean age 59.8 ± 14.7 years), 99 received DOACs and 72 received warfarin. LVT resolution was higher with DOACs (66.7% vs. 50%, HR 2.0, 95% CI 1.07–3.73, p = 0.029), with a trend toward faster thrombus resolution (185 vs. 220 days, p = 0.214) though statistically not significant. DOAC use remained an independent predictor of LVT resolution, regardless of antiplatelet use. Major bleeding (2.9%), thromboembolic events (5.3%), and mortality (5.3%) were similar between groups. Conclusions: DOAC therapy was associated with higher LVT resolution rates and a comparable safety profile to warfarin. Further randomized clinical trials are warranted to validate these findings.Keywords
This publication has 29 references indexed in Scilit:
- Direct Oral Anticoagulants Versus Warfarin for the Treatment of Left Ventricular Thrombus: A Multicenter Retrospective Observational StudyThe American Journal of Cardiology, 2024
- Apixaban in Patients With Post-Myocardial Infarction Left Ventricular Thrombus: A Randomized Clinical TrialCJC Open, 2022
- Treatment of Left Ventricular Thrombus With Direct Oral Anticoagulants: A Retrospective Observational StudyThe American Journal of Medicine, 2020
- Direct Oral Anticoagulants Compared to Vitamin K Antagonist for the Management of Left Ventricular ThrombusESC Heart Failure, 2020
- Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular ThrombiJAMA Cardiology, 2020
- Management of Left Ventricular Thrombi with Direct Oral Anticoagulants: Retrospective Comparative Study with Vitamin K AntagonistsClinical Drug Investigation, 2020
- Select Drug-Drug Interactions With Direct Oral AnticoagulantsJACC, 2020
- Efficacy of Direct Acting Oral Anticoagulants in Treatment of Left Ventricular ThrombusThe American Journal of Cardiology, 2019
- Left Ventricular ThrombusJACC, 2019
- Frequency of Left Ventricular Thrombus in Patients With Anterior Wall Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention and Dual Antiplatelet TherapyThe American Journal of Cardiology, 2010